Clinical Trial Update: Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Dual CD19/CD22 CAR-T cell therapy is being studied in Phase 1/2 trials for relapsed and refractory Non-Hodgkin lymphoma; the current trial status is not provide…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• CD19/CD22 dual-specificity CAR-T cell therapy

Snippet

Sponsor: Ruijin Hospital | Conditions: Lymphoma | Phase 1, Phase 2 | Status: UNKNOWN